Another key driver is the diversification of therapeutic area, i.e., obesity and management of cardio metabolic risk to expand market opportunity
During titration phases, limit prefilling to 1-2 doses at most
Compared to hGH, AOD9604 offered similar adipose tissue effects without significantly increasing systemic growth factors, such as IGF-1
The biological drivers of obesity, specifically the hunger hormones and metabolic set points that pushed your weight up in the first place, come back
I think thats the hardest part.
With that expiration, generic GLP-1 drugs were available in India, the worlds most populous country